Loading...
•
Dec 31, 2024
Precigen Q4 2024 Earnings Report
Precigen reported its Q4 2024 results, completing a year focused on advancing PRGN-2012 toward commercialization and maintaining financial discipline.
Key Takeaways
In Q4 2024, Precigen reported $1.19 million in revenue and a net loss of $19.73 million, with an EPS of -$0.06. The company continued preparations for the anticipated commercial launch of PRGN-2012 in 2025 and successfully extended its cash runway into 2026.
Q4 revenue reached $1.19 million.
Q4 net loss was $19.73 million, with EPS of -$0.06.
The company completed pre-BLA meetings and is aligned with the FDA for PRGN-2012 submission.
Cash, cash equivalents, and investments totaled $97.9 million at year-end 2024.
Revenue by Segment
Forward Guidance
Precigen expects to achieve FDA approval and launch PRGN-2012 in 2025, expanding its reach and revenue base.
Positive Outlook
- BLA submission for PRGN-2012 planned and aligned with FDA.
- Cash runway extended into 2026.
- Strong clinical trial data supporting PRGN-2012 efficacy.
- Active preparations for commercial and manufacturing scale-up.
- Estimated market opportunity of 27,000 adult RRP patients in the US.
Challenges Ahead
- Continued quarterly net losses.
- Revenue remains low prior to commercial launch.
- Significant impairment charges recorded in 2024.
- Dependence on regulatory milestones for growth.
- High R&D expenses continue to weigh on financials.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...